ClinicalTrials.gg
RecruitingNCT05940272Updated Oct 13, 2026

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

An interventional study of Hematolo-GIST Training and Participants Appointment in Lymphoma, B-Cell, Lymphoma and Large-cell Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Primary conditionLymphoma, Large B-Cell, DiffuseRegistry: Lymphoma, B-CellReclassifiedWhy we changed it
Registry
Lymphoma, B-Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Large B-Cell, Diffuse
Why
  1. The study's listed conditions name Lymphoma, Large B-Cell, Diffuse, a narrower term within Lymphoma, B-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Lymphoma, Large B-Cell, Diffuse by Memorial Sloan Kettering Cancer Center — 3 open to participants now, 8 under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · Memorial Sloan Kettering Cancer Center.

Planned enrollment
10th of 20
48 · median 45
Started
2023
the only one that year
No phase
3 of 40
1 open now
Registered
38th of 40
by date

Among the 40 studies in Lymphoma, Large B-Cell, Diffuse by Memorial Sloan Kettering Cancer Center, this one is the 10th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2023, is one of 3 with no phase, and was the 38th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

3 of the 40 studies in Lymphoma, Large B-Cell, Diffuse by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Lymphoma, Large B-Cell, Diffuse by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.

03

Conditions studied

  • Lymphoma, B-Cell
  • Lymphoma
  • Large-cell Lymphoma
  • Large B-cell Lymphoma
  • DLBCL - Diffuse Large B Cell Lymphoma
  • Mediastinal B-Cell Diffuse Large Cell Lymphoma

Browse trials for

Keywords

  • oncologist
  • hemotologic oncologist
  • lymphoma
  • large cell lymphoma
  • large b-cell lymphoma
  • DLBCL
  • Diffuse Large B Cell Lymphoma
  • Mediastinal B-Cell Diffuse Large Cell Lymphoma
  • Hematolo-GIST
  • 23-164
  • Memorial Sloan Kettering Cancer Center
04

In context

Lymphoma, Large B-Cell, Diffuse Reclassified

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

This study's planned enrollment of 48 is close to the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Lead sponsor

Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.

Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.

Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, B-Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Providers

  • Currently a an MSK provider caring for patients with DLBCL (including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and treated as large-cell lymphoma)

Patients

  • Per medical record, is currently being treated by a provider who is participating in this study (for the purposes of this study, "treating provider" will be defined as any provider who provides care related to the patient's lymphoma diagnosis)
  • Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma
  • Per medical record, relapse/ disease within 12 months of 4 cycles of therapy OR relapse after 2 cycles of later line therapy or or stem cell transplant (ASCT)
  • Self-identify as Black and/or White
  • Per medical record, 18 years of age or older
  • Per self-report, fluent in English**

    • Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:

      1. How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
      2. What is your preferred language for healthcare? (must respond English)

Exclusion criteria

Exclusion Criteria:

Providers

  • Per self-report, planning to leave the cancer center in the next 12 months

Patients

  • Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11
  • Per research staff judgment and/or self-report, too ill or weak to complete study procedures
  • Per medical record or self-report, receiving hospice care at the time of enrollment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

06

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Hematologists

    Hematologists will be recruited from the lymphoma clinics at MSK

    Behavioral: Hematolo-GIST Training

  • Experimental
    Participants Patients

    Participant patients are being treated by a hematologic oncologist participating in this study

    Behavioral: Participants Appointment

Interventions

  • BehavioralHematolo-GIST Training

    Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.

  • BehavioralParticipants Appointment

    Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.

07

What researchers measure

Primary outcomes

  1. Feasibility of the Hematolo-GIST intervention among hematologists and participants

    Feasbility is defined as ≥70% of screened eligible hematologists and participants enrolling in the study and ≥80% of hematologists learning the approach

    Time frame: Up to 1 year

08

Study locations

1 of 2 sites recruiting
  • Memorial Sloan Kettering Cancer Center (All protocol activities)
    New York, New York 10065, United States
    Recruiting
    • Kelly McConnell, PhD · Contact646-888-0026
  • NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only)
    New York, New York 10065, United States
    Not yet recruiting
    • Alan Astrow, MD · Contact646-962-2330
09

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jul 2028, 60 months after the start.

Of 40 non-industry interventional studies with no phase under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 144. This study's planned 60 months is below that.

Counting every sponsor, half of 41 studies reached it within 73 months; a quarter within 42 and three quarters within 137.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2023
First posted
Jul 11, 2023
StartActual
Jul 3, 2023
Primary completionEst.
Jul 3, 2028
CompletionEst.
Jul 3, 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05940272
Responsible party
Sponsor
First posted
Jul 11, 2023
Start date
Jul 3, 2023
Primary completion
Jul 3, 2028 (estimated)
Completion
Jul 3, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Kelly McConnell, PhD
Contact
McConneK@mskcc.org
646-888-0026
Revecca Saracino, PhD
Contact
jamesr@mskcc.org
646-888-0263
Kelly McConnell, PhD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion